SCHEMBL3537199

SCHEMBL3537199

CC1CCN(c2cc(N3CCN(C(=O)OCc4ccccc4)CC3)ccc2[N+](=O)[O-])CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR174 Q9BXC1 2/20 0.57
ALDH1A1 P00352 6/20 0.53
MAPT P10636 6/20 0.53
LIN28A Q9H9Z2 1/20 0.49
TMEM97 Q5BJF2 9/20 0.49
SIGMAR1 Q99720 9/20 0.49
LMNA P02545 3/20 0.49
HTR1A P08908 3/20 0.49
HRH2 P25021 3/20 0.49
HRH1 P35367 3/20 0.49
HRH3 Q9Y5N1 3/20 0.49
ADRA2A P08913 2/20 0.49
ADRA2B P18089 2/20 0.49
HTR2A P28223 2/20 0.49
HTR2C P28335 2/20 0.49
HTR2B P41595 2/20 0.49
ADRA2C P18825 2/20 0.49
DRD1 P21728 1/20 0.49
HTR1B P28222 1/20 0.49
HTR1E P28566 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18154906 0.83 TMEM97 (0.55) ALDH1A1MAPTTMEM97SIGMAR1LMNA
SCHEMBL3417273 0.83 MAPT (0.53) GPR174ALDH1A1MAPTLIN28ATMEM97
SCHEMBL29446168 0.83 TMEM97 (0.55) ALDH1A1MAPTTMEM97SIGMAR1LMNA
SCHEMBL27691387 0.83 MAPT (0.56) GPR174ALDH1A1MAPTLMNAMEN1
SCHEMBL3540449 0.82 ALDH1A1 (0.60) GPR174ALDH1A1MAPTLMNACYP2C19
SCHEMBL31157984 0.82 ALDH1A1 (0.60) GPR174ALDH1A1MAPTLMNACYP2C19
SCHEMBL3821618 0.81 MAPT (0.56) GPR174ALDH1A1MAPTTMEM97SIGMAR1
SCHEMBL3537287 0.81 GPR174 (0.47) GPR174ALDH1A1MAPTLIN28ALMNA
SCHEMBL14227607 0.80 TMEM97 (0.51) ALDH1A1MAPTTMEM97SIGMAR1LMNA
SCHEMBL25301725 0.79 SMN1; SMN2 (0.57) ALDH1A1MAPTTMEM97SIGMAR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705042-B2 Class of arylamide compounds useful as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2010-04-27 US disclosed
US-7705042-B2 Class of arylamide compounds useful as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2010-04-27 US disclosed
US-7705042-B2 Class of arylamide compounds useful as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2010-04-27 US disclosed
EP-1807407-B1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2009-07-29 EP disclosed
CN-101084208-A Aromatic amides as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2007-12-05 CN disclosed
EP-1807407-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-18 EP disclosed
US-20060100201-A1 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-11 US disclosed
WO-2006047504-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100201-A1 Inhibitors of c-fms kinase MUSK, FLT3, FES GPR174 969/4885ALDH1A1 4796/4885MAPT 159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.